Hylomorph is an innovative Medtech company engineering biomaterials to optimize the interface between implants and their surrounding biological tissues. We aim at preventing post operative complications in implantable medical devices. Our mission is to improve quality of life in patients and the quality of care by health professionals.​Our proprietary CellSense technology was developed in the cutting-edge laboratories of the Swiss Federal Institute of Technology (ETH Zurich). Hylomorph's first product, Hylomate, has demonstrated outstanding performance in limiting the foreign body reaction and fibrotic buildup in pre-clinical settings and is currently undergoing first-in-man clinical trials in Germany.